Open Orphan PLC
LSE:ORPH
Intrinsic Value
Open Orphan Plc provides pharmaceutical development services. [ Read More ]
The intrinsic value of one ORPH stock under the Base Case scenario is 13.27 GBX. Compared to the current market price of 10 GBX, Open Orphan PLC is Undervalued by 25%.
Valuation Backtest
Open Orphan PLC
Run backtest to discover the historical profit from buying and selling ORPH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Open Orphan PLC
Current Assets | 42.2m |
Cash & Short-Term Investments | 28.4m |
Receivables | 13.3m |
Other Current Assets | 499k |
Non-Current Assets | 9.1m |
PP&E | 3.1m |
Intangibles | 6m |
Current Liabilities | 29.8m |
Accounts Payable | 28.9m |
Other Current Liabilities | 896k |
Non-Current Liabilities | 1.4m |
Long-Term Debt | 737k |
Other Non-Current Liabilities | 660k |
Earnings Waterfall
Open Orphan PLC
Revenue
|
48.5m
GBP
|
Operating Expenses
|
-42.3m
GBP
|
Operating Income
|
6.1m
GBP
|
Other Expenses
|
-6.9m
GBP
|
Net Income
|
-776k
GBP
|
Free Cash Flow Analysis
Open Orphan PLC
ORPH Profitability Score
Profitability Due Diligence
Open Orphan PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Open Orphan PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
ORPH Solvency Score
Solvency Due Diligence
Open Orphan PLC's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Open Orphan PLC's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ORPH Price Targets Summary
Open Orphan PLC
According to Wall Street analysts, the average 1-year price target for ORPH is 29.87 GBX .
Shareholder Return
ORPH Price
Open Orphan PLC
Average Annual Return | 263.68% |
Standard Deviation of Annual Returns | 255.48% |
Max Drawdown | -81% |
Market Capitalization | 67.1m GBX |
Shares Outstanding | 670 929 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Open Orphan Plc provides pharmaceutical development services. The firm is engaged in the testing of vaccines and antivirals using human clinical trials. The firm has a presence in the United Kingdom, Ireland, France and Netherlands. The Company, through its subsidiary hVIVO Limited, is also engaged in the data platform business. hVIVO Limited has built up databases of infectious disease progression data and the Company is populating its Open Orphan Health Data platform with hVIVO data. The firm also operates through its subsidiary Venn Life Sciences, which is an integrated drug development partner. Venn Life Sciences offers a combination of drug development consultancy, clinical trial design and execution to create, plan and execute drug development programs for its customers.
Contact
IPO
Employees
Officers
The intrinsic value of one ORPH stock under the Base Case scenario is 13.27 GBX.
Compared to the current market price of 10 GBX, Open Orphan PLC is Undervalued by 25%.